Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.35 |
| ▸ | PPARA | Q07869 | 8/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6154669 | 0.94 | MEN1 (0.36) | LMNAPOLBHPGDL3MBTL1MEN1 | |
| SCHEMBL7491122 | 0.90 | MEN1 (0.35) | HPGDL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL8049696 | 0.88 | ALDH1A1 (0.37) | LMNAPOLBHPGDL3MBTL1MEN1 | |
| SCHEMBL6153461 | 0.88 | CYP4F2 (0.34) | LMNAPOLBHPGDMEN1KMT2A | |
| SCHEMBL6153142 | 0.87 | CYP2C9 (0.37) | LMNAHPGDL3MBTL1MEN1KMT2A | |
| SCHEMBL6946876 | 0.86 | TTR (0.35) | LMNAPOLBHPGDL3MBTL1MEN1 | |
| SCHEMBL6949307 | 0.86 | CYP2C9 (0.32) | LMNAPOLBHPGDMEN1KMT2A | |
| SCHEMBL6153189 | 0.85 | CYP2C9 (0.32) | LMNAPOLBHPGDL3MBTL1MEN1 | |
| SCHEMBL7843083 | 0.85 | ALDH1A1 (0.41) | HPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL7836265 | 0.84 | SLC7A5 (0.39) | LMNAPOLBHPGDL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307449-B1 | 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMA (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-6653313-B2 | For treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders | WARNER-LAMBERT COMPANY LLC | 2003-11-25 | — | — | US | disclosed |
| US-20020161006-A1 | 1,4-dihydropyridine compounds as bradykinin antagonists | KAWAMURA MITSUHIRO (US) | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161006-A1 | 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, HRH4 | PPARG 4564/4885PPARA 4357/4885LMNA 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.